Molecular approaches to achieving control of gene expression by drug intervention at the transcriptional level

Anti-Cancer Drug Design

Volumn 14, Issue 1, 1999, Pages 1-9

  Zewail Foote, Maha ^a   Hurley, Laurence H ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Antitumour drugs; DNA bending; Protein DNA complexes; Transcriptional control

Indexed keywords

CELL NUCLEUS RECEPTOR; CISPLATIN; DNA; RACHELMYCIN;

DNA SEQUENCE; DNA STRUCTURE; DRUG DESIGN; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA, NEOPLASM; DRUG DESIGN; GENE EXPRESSION REGULATION; HUMANS; TRANSCRIPTION, GENETIC;

EID: 0032911152     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., Norton L. (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Journal of Clinical Oncology, 14, 737.
2. Beeley L.J., Duckworth D.M. (1996) The impact of genomics on drug design. Drug Discovery Today, 1, 474.
3. Bellorini M., Moncollin V., d'Incalci M., Mongelli N., Mantovani R. (1995) Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription. Nucleic Acids Research, 23, 1657.
4. Bishop J.M. (1987) The molecular genetics of cancer. Science, 235, 305.
5. Bishop J.M. (1991) Molecular themes in oncogenesis. Cell, 64, 235.
6. Bonham M.A., Brown S., Boyd A.L., Brown P.H., Bruckenstein D.A., Hanvey J.C., Thomson S.A., Pipe A., Hassman E, Bisi J.E., Froehler B.C., Matteucci M.D., Wagner R.W., Noble S.A., Babiss L.E. (1995) An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Research, 23, 1197.
7. Brunton V.G., Workman P. (1993) Cell-signaling targets for antitumour drug development. Cancer Chemotherapy and Pharmacology, 32, 1.
8. Burley S.K., Roeder R.G. (1996) Biochemistry and structural biology of transcription factor II D (TFIID) Annual Reviews in Biochemistry, 65, 769.
9. Chiang S.Y., Welch J., Rauscher F.J. III, Beerman T.A. (1994) Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA. Biochemistry, 33, 7033.
10. Dickinson L.A., Gulizia R.J., Trauger J.W., Baird E.E., Mosier D.E., Gottesfeld J.M., Dervan P.B. (1998) Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. Proceedings of the National Academy of Sciences, USA, 95, 12890.
11. 2+ complex on DNA: a new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex. Journal of Medicinal Chemistry, 3, 498.
12. Gelbert L.M., Gregg R.E. (1997) Will genetics really revolutionize the drug discovery process? Current Opinions in Biotechnology, 8, 669.
13. Good L., Nielsen P.E. (1998) Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nature Biotechnology, 16, 355.
14. Hansen M., Lee S.J., Cassady J.M., Hurley L.H. (1996) Molecular details of the structure of a psorospermin-DNA covalent/intercalation complex and associated DNA sequence selectivity. Journal of the Americal Chemical Society, 24, 5553.
15. Helénè C., Toulmé J.J. (1989) Control of gene expression by oligodeoxynucleotides covalently linked to intercalating agents and nucleic acid-cleaving reagents. In Topics in Molecular and Structural Biology. Oligonucleotides: Antisense Inhibitors of Gene Expression. Cohen J.S. (ed.), p. 137. CRC Press: Boca Raton, FL.
16. Ho S.N., Boyer S.H., Schreiber S.L., Danishefsky S.J., Crabtree G.R. (1994) Specific inhibition of formation of transcription complexes by a calicheamicin oligosaccharide: a paradigm for the development of transcriptional antagonists. Proceedings of the National Academy of Sciences, USA, 91, 9203.
17. Hudziak R.M., Lewis G.D., Winget M., Fendly B.M., Shepard H.M., Ullrich A. (1989) p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Molecular and Cellular Biology, 9, 1165.
18. Hurley L.H. (1989) DNA and associated targets for drug design. Journal of Medicinal Chemistry, 32, 2027.
19. Kim J.L., Nikolov D.B., Burley S.K. (1993) Co-crystal structure of TBP recognizing the minor groove of a TATA element. Nature, 365, 520.
20. Kwok Y., Hurley L.H. (1998) Topoisomerase II site-directed alkylation of DNA by psorospermin and its effect on topoisomerase II-mediated DNA cleavage. Journal of Biological Chemistry, 49, 33020.
21. Kwok Y., Zeng Q., Hurley L.H. (1998) Topoisomerase II-mediated site-directed alkylation of DNA by psorospermin and its use in mapping other topoisomerase II poison binding sites. Proceedings of the National Academy of Sciences, USA, 95, 13531.
22. 2+ self-assembly model formed in the presence of topoisomerase II. Journal of Biological Chemistry, in press.
23. Lewis G.D., Figari I., Fendly B., Wong W.L., Carter P., Gorman C., Shepard H.M. (1993) Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunology, Immunotherapy, 37, 255.
24. Luger K., Mader A.W., Richmond R.K., Sargent D.F., Richmond T.J. (1997) Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature, 389, 251.
25. Møllegaard N.E., Buchardt O., Egholm M., Nielsen P.E. (1994) Peptide nucleic acid-DNA strand displacement loops as artificial transcription promoters. Proceedings of the National Academy of Sciences, USA, 91, 3892.
26. Moore B.M. II, Seaman F.C., Hurley L.H. (1997) NMR-based model of an ecteinascidin 743-DNA adduct. Journal of the American Chemical Society, 119, 5475.
27. Nielsen P.E., Egholm M., Berg R.H., Buchardt O. (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science, 254, 1497.
28. Nielsen P.E., Egholm M., Buchardt O. (1994) Sequence-specific transcription arrest by peptide nucleic acid bound to the DNA template strand. Gene, 149, 139.
29. Nikolov D.B., Burley S.K. (1997) RNA polymerase II transcription initiation: a structural view. Proceedings of the National Academy of Sciences, USA, 97, 15.
30. Pil P.M., Lippard S.J. (1992) Specific binding of chromosomal protein HMGl to DNA damaged by the anticancer drug cisplatin. Science, 256, 234.
31. Pommier Y., Kohlhagen G., Bailly C., Waring M., Mazumder A., Kohn K.W. (1996) DMA sequence-and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the caribbean tunicate Ecteinascidia turbinata. Biochemistry, 35, 13303.
32. Powis G., Workman P. (1994) Signalling targets for the development of cancer drugs. Anti-Cancer Drug Design, 9, 263.
33. Rice J.A., Crothers D.M., Pinto A.L., Lippard S.J. (1988) The major adduct of the antitumor drug cis-diamminedichloro-platinum(II) with DNA bends the duplex by ~40° toward the major groove. Proceedings of the National Academy of Sciences, USA, 85, 4158.
34. Richmond T.J., Finch J.T., Rushton B., Rhodes D., Klug A. (1984) Structure of the nucleosome core particle at 7 Å resolution. Nature, 311, 532.
35. Rink S.M., Yarema K.J., Solomon M.S., Paige L.A., Tadayoni-Rebek B.M., Essigmann J.M., Croy R.G. (1996) Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor. Proceedings of the National Academy of Sciences, USA, 93, 15063.
36. Rosen J., Day A., Jones T.K., Jones E.T., Nadzan A.M., Stein R.B. (1995) Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small-molecule drug discovery. Journal of Medicinal Chemistry, 38, 4855.
37. Sakai R., Jares-Erijman E.A., Manzanares I., Silva Elipe M.V, Rinehart K.L. (1996) Ecteinascidins: putative biosynthetic precursors and absolute stereochemistry. Journal of the American Chemical Society, 118, 9017.
38. Seaman F.C., Hurley L.H. (1998) Molecular basis for the DNA sequence selectivity of ecteinascidin 736 and 743: evidence for the dominant role of direct readout via hydrogen bonding. Journal of the American Chemical Society, 120, 13028.
39. Shen L.L., Kohlbrenner W.E., Weigl D., Baranowski J. (1989) Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. Journal of Biological Chemistry, 264, 2973.
40. Shepard H.M., Lewis G.D., Sarup J.C., Fendly B.M., Maneval D., Mordenti J., Figari I., Kotts C.E., Palladino M.A. Jr, Ullrich A., Slamon D. (1991) Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. Journal of Clinical Immunology, 11, 117.
41. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. (1987) Human beast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177.
42. Su W., Jackson S., Tjian R., Echols H. (1991) DNA looping between sites for transcriptional activation: self-association of DNA-bound Sp1. Genes and Development, 5, 820.
43. Sun D., Hurley L.H. (1994a) Cooperative bending of the 21-base-pair repeats of the SV40 viral early promoter by human Sp1. Biochemistry, 33, 9578.
44. Sun D., Hurley L.H. (1994b) Binding of Sp1 to the 21-base-pair repeat region of SV40 DNA: effect of intrinsic and drug-induced DNA bending between GC boxes. Gene, 149, 165.
45. Sun D., Hurley L.H. (1995) TBP binding to the TATA box induces a specific downstream unwinding site that is targeted by pluramycin. Chemistry and Biology, 2, 457.
46. Trauger J.W., Baird E.E., Dervan P.B. (1998) Recognition of 16 base pairs in the minor groove of DNA by a pyrrole-imidazol polyamide dimer. Journal of the American Chemical Society, 120, 3534.
47. Treiber D.K., Zhai X., Jantzen H.M., Essigmann J.M. (1994) Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor) Proceedings of the National Academy of Sciences, USA, 91, 5672.
48. Veber D.F., Drake F.H., Gowen M. (1997) The new partnership of genomics and chemistry for accelerated drug development. Current Opinions in Chemistry and Biology, 1, 151.
49. Vogelstein B., Kinzler K. (1993) The multistep nature of cancer. Trends in Genetics, 9, 138.
50. White S., Baird E.E., Dervan P.B. (1997) On the pairing rules for recognition in the minor groove of DNA by pyrroleimidazole polyamides. Chemistry and Biology, 4, 569.
51. White S., Szewczyk J.W., Turner J.M., Baird E.E., Dervan P.B. (1998) Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands. Nature, 391, 468.